Better Education on Glomerulonephritis

Annenberg Center for Health Sciences
  • 0.0 (0)
  • MEDICINE

Nephrology experts Jai Radhakrishnan, MD, and Dana Rizk, MD, delve into the complex disease of immunoglobulin A nephropathy (IgAN), addressing unmet treatment needs and novel frontiers of therapy. They discuss IgAN as a chronic disease, reviewing its pathophysiologic basis, morbidity and mortality including significant reductions in health-related quality of life, existing treatment options, and evolving new targeted therapies. The experts review treatment strategies, highlight case studies and share their experience improving long-term health outcomes.

Episodes

  1. 07/28/2022

    Conclusion

    Conclusion

    1 min

  2. 07/28/2022

    Case Presentation

    Case presentation

    5 min

  3. 07/28/2022

    Emerging Therapies: Efficacy and Safety Data from Phase 3 Trials

    Phase 3 trials: targeted-release formulation-budesonide, atrasentan, sparsentan, iptacopan narsolimab Emerging therapies in Phase 2 trials

    6 min

  4. 07/28/2022

    IgAN Treatment Strategies

    KDIGO Recommendations Unmet Needs in Clinical Management Novel Approaches

    7 min

  5. 07/28/2022

    Proteinuria in IgAN

    Severity as a negative prognostic factor for IgAN Proteinuria reduction as a treatment goal Proteinuria reduction as a meaningful secondary endpoint for improved renal outcomes Proteinuria reduction and ESRD progression

    7 min

  6. 07/28/2022

    Diagnosis & Prognosis of IgAN

    Clinical Presentation KDIGO Diagnosis KDIGO Prognosis Initial Assessment Scoring Tools: MEST-C score, International IgAN Prediction Tool

    8 min
  7. Introduction to IgAN

    07/28/2022

    Introduction to IgAN

    Epidemiology Pathophysiology Disease Burden

    8 min
  • 7 Episodes

About

Nephrology experts Jai Radhakrishnan, MD, and Dana Rizk, MD, delve into the complex disease of immunoglobulin A nephropathy (IgAN), addressing unmet treatment needs and novel frontiers of therapy. They discuss IgAN as a chronic disease, reviewing its pathophysiologic basis, morbidity and mortality including significant reductions in health-related quality of life, existing treatment options, and evolving new targeted therapies. The experts review treatment strategies, highlight case studies and share their experience improving long-term health outcomes.

Information